Want to join the conversation?
$CSC 1Q16 Call: Our GBS revenue was down 4% YoverY and our IS&S revenue was up 1% YoverY driven primarily by growth in our BPS business. Our consulting revenue was down 8% YoverY. We continue to see good growth in our UK consulting business and US consulting business still sequentially declined. Our application revenue was down 7% YoverY.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.